[{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Il-Yang Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Mirabegron","moa":"Beta-3 adrenergic receptor","graph1":"Urology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Il-Yang Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Il-Yang Pharm"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seoul National University Hospital \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Amgen Inc"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pharos iBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PHI-101","moa":"Chk2","graph1":"Oncology","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Pharos iBio","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Pharos iBio"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pharos iBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PHI-101","moa":"Chk2","graph1":"Oncology","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Pharos iBio","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Pharos iBio"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Samjin Pharmaceutical | Medtronic plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Seoul National University Hospital \/ Samjin Pharmaceutical | Medtronic plc","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Samjin Pharmaceutical | Medtronic plc"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Focused Ultrasound Foundation | Synex Consulting Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Focused Ultrasound Foundation | Synex Consulting Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Focused Ultrasound Foundation | Synex Consulting Ltd"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Neurology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seoul National University Hospital \/ CSL Vifor","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ CSL Vifor"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Hana Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Seoul National University Hospital \/ Hana Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Hana Pharm"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ezetimibe","moa":"Niemann-Pick C1-like protein 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Whanin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Whanin Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Whanin Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Yonsei University | Asan Medical Center | Samsung Medical Center | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Yonsei University | Asan Medical Center | Samsung Medical Center | Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Yonsei University | Asan Medical Center | Samsung Medical Center | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"YUNGJIN PHARM. CO. LTD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Korean Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Korean Cancer Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Korean Cancer Study Group"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Samjin pharm Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clopidogrel","moa":"Purinergic receptor P2Y12","graph1":"Immunology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Samjin Pharmaceutical"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seoul National University Hospital \/ Inovio Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Inovio Pharmaceuticals"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Semaxanib","moa":"Thrombopoietin receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Kyowa Kirin"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Neuramedy","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"NM-101","moa":"Toll-like-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sitravatinib","moa":"tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ BeOne Medicines"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AJH-2947","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seoul National University Hospital \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Ensol BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"C1K","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Ensol BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Ensol BioSciences"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Glaceum","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HGR4113","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Seoul National University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Seoul National University Hospital \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Glaceum","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Glaceum","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSG4112","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Seoul National University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Seoul National University Hospital"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Kyongbo Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Kyongbo Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Kyongbo Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Kyongbo Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Dalim BioTech","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Dalim BioTech","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Dalim BioTech"}]
Find Clinical Drug Pipeline Developments & Deals by Seoul National University Hospital
Details :
NM-101 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Ezetimibe is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Ischemic Stroke.
Details :
Naltrexone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Details :
Durvalumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Details :
Rivaroxaban is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Atrial Fibrillation.
Details :
Mirabegron is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder, Overactive.
Details :
Clopidogrel is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Antiphospholipid Syndrome.
Details :
Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Pain, Postoperative.
Reset All
